Identification of Potent Ebola Virus Entry Inhibitors with Suitable Properties for in Vivo Studies
作者:Hu Liu、Ye Tian、Kyungae Lee、Pranav Krishnan、May Kwang-Mei Wang、Sean Whelan、Emily Mevers、Veronica Soloveva、Benjamin Dedic、Xinyong Liu、James M. Cunningham
DOI:10.1021/acs.jmedchem.8b00704
日期:2018.7.26
an adamantane dipeptide piperazine 3.47 that inhibits Ebola virus (EBOV) infection by targeting the essential receptor Niemann–Pick C1 (NPC1). The physicochemical properties of 3.47 limit its potential for testing in vivo. Optimization by improving potency, reducing hydrophobicity, and replacing labile moieties identified 3.47 derivatives with improved in vitro ADME properties that are also highly
先前的研究确定了金刚烷二肽哌嗪3.47,其通过靶向必需受体Niemann–Pick C1(NPC1)抑制埃博拉病毒(EBOV)感染。3.47的理化特性限制了其在体内测试的潜力。通过提高效力,降低疏水性和取代不稳定部分进行优化,确定为3.47具有改善的体外ADME特性的衍生物,对EBOV感染也具有很高的活性,包括在50%正常人血清(NHS)存在下进行测试时。此外,3A4被认为是代谢这些化合物的主要细胞色素P450亚型,因此,在存在CYP3A4抑制剂ritonavir的存在下进行测试时,小鼠微粒体的稳定性得到了显着改善,该药物已被批准用于临床作为抗HIV药物的增强剂。EBOV抑制剂与利托那韦的口服给药产生的药代动力学特征支持了用于小鼠功效研究的双向给药方案。